Cordycepin Reverses Cisplatin Resistance in Non-small Cell Lung Cancer by Activating AMPK and Inhibiting AKT Signaling Pathway

Cordycepin Reverses Cisplatin Resistance in Non-small Cell Lung Cancer by Activating AMPK and Inhibiting AKT Signaling Pathway

Cisplatin (DDP) is the first-line chemotherapeutic agent against lung cancer. However, the therapeutic effect of DDP loses over time due to the acquired drug resistance in non-small cell lung cancer (NSCLC) cells. In recent years, the role of the traditional Chinese medicine (TCM) cordycepin (Cor) i...

Full description

Bibliographic Details
Main Authors: Xiao-Zhong Liao, Ying Gao, Hong-Wei Zhao, Mi Zhou, Dan-Lei Chen, Lan-Ting Tao, Wei Guo, Ling-Ling Sun, Chu-Ying Gu, Han-Rui Chen, Zhi-Wei Xiao, Jia-Xing Zhang, Mei-Fang He, Li-Zhu Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
NSCLC
cisplatin
resistance
cordycepin
AMPK
AKT
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2020.609285/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2020.609285/full

Similar Items